SENTARA COMMUNITY PLAN
(MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

Drug Requested: Cimzia™ (certolizumab) **Lyophilized (J-0717) (Medical)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Weight: _____ **Date:** _____

- **Cimzia™ is available under both Medical and Pharmacy benefits**

DIAGNOSIS	Recommended Dose
❑ **Moderate to Severe Chronic Plaque Psoriasis**	• 400 mg (given as 2 subcutaneous injections of 200 mg each) initially weeks 0, 2 and 4. • 200 mg every other week or 400 mg every 4 weeks. • Six syringes/vials allowed in the initial 28 days • Two syringes/vials per 28 days for maintenance
❑ **Crohn's Disease – Moderate to Severe Active**	• 400 mg initially at weeks 0, 2 and 4 • If response occurs, follow with 400 mg every four weeks • Six syringes/vials allowed in the initial 28 days • Two syringes/vials per 28 days after induction period
❑ **Rheumatoid Arthritis – Moderate to Severe**	• 400 mg initially at weeks 0, 2 and 4 • Followed by 200 mg every other week • Six syringes/vials allowed in the initial 28 days • Two syringes/vials per 28 days after induction period

(Continued on next page)

DIAGNOSIS	Recommended Dose
❑ **Psoriatic Arthritis**	• 400 mg initially at weeks 0, 2 and 4 • 200 mg every other week; for maintenance dosing, or 400 mg every 4 weeks • Six syringes/vials allowed in the initial 28~~54~~ days • Two syringes/vials per 28 days for maintenance
❑ **Ankylosing Spondylitis**	• 400 mg (given as 2 subcutaneous injections of 200 mg each) initially weeks 0, 2 and 4 • 200 mg every other week or 400 mg every 4 weeks. • Six syringes/vials allowed in the initial 28 days • Two syringes/vials per 28 days for maintenance
❑ **Non-Radiographic Axial Spondyloarthritis (nr-axSpA)**	• 400 mg (given as 2 subcutaneous injections of 200 mg each) initially weeks 0, 2 and 4 • 200 mg every other week or 400 mg every 4 weeks. • Six syringes/vials allowed in the initial 28 days • Two syringes/vials per 28 days for maintenance

❑ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

CLINCIAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Prescriber is: ❑ **Gastroenterologist** ❑ **Rheumatologist** ❑ **Dermatologist**

❑ **Diagnosis: Moderate to Severe Chronic Plaque Psoriasis**

❑ Member has moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy

AND

❑ Have not responded adequately trial of topical agents (e.g., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or Vitamin D analogues)

AND

❑ Have not responded adequately to a 3-month minimum trial of phototherapy (e.g. Psoralens with UVA light (PUVA) OR UVB with coal tar or dithranol)

AND

❑ Trial and failure of **TWO (2)** of the **PREFERRED**:

❑ Humira®	❑ Enbrel®	❑ Infliximab

(Continued on next page)

❑ Diagnosis: Crohn's Disease – Moderate to Severe Active

❑ Member has trial and failure of a compliant regimen of oral corticosteroids (budesonide 9mg daily for 8 weeks) or high dose steroids (40-60 mg prednisone) (moderate to severe CD) unless contraindicated or intravenous corticosteroids (severe and fulminant CD or failure to respond to oral corticosteroids)

AND

❑ Member tried and failed **at least ONE previous 5-Aminosalicylates or immunomodulator therapy below:**

❑ methotrexate	❑ azathioprine	❑ auranofin
❑ sulfasalazine	❑ oral aminosalicylates	❑ leflunomide
❑ 6-mercaptopurine	❑ Apriso®	❑ balsalazide
❑ Pentasa®		

AND

❑ Member has tried and failed:

❑ Humira®	❑ Infliximab

❑ Diagnosis: Rheumatoid Arthritis – Moderate to Severe

❑ Trial and failure of, contraindication, or adverse reaction to methotrexate

AND

❑ Trial and failure of **at least ONE (1) other DMARD** (**check each tried**):

❑ auranofin	❑ azathioprine	❑ leflunomide
❑ hydroxychloroquine	❑ sulfasalazine	

AND

❑ Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

❑ Humira®	❑ Enbrel®	❑ Infliximab

❑ Diagnosis: Psoriatic Arthritis

❑ Trial and failure of methotrexate

OR

(Continued on next page)

- ❑ Requested medication will be used in conjunction with methotrexate

OR

- ❑ Member has a contraindication to methotrexate (e.g., alcohol abuse, cirrhosis, chronic liver disease, or other contraindication);

AND

- ❑ Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

❑ Humira®	❑ Enbrel®	❑ Infliximab

❑ Diagnosis: Ankylosing Spondylitis

- ❑ Trial and failure of an adequate trial of at least **two (2) NSAIDS**

OR

- ❑ Use of NSAIDs is contraindicated in member

AND

- ❑ Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

❑ Humira®	❑ Enbrel®	❑ Infliximab

❑ Diagnosis: A Non-Radiographic Axial Spondyloarthritis

- ❑ Member has a diagnosis of Active Non-radiographic Axial Spondylarthritis (nr-axSpA)

Medication being provided by (check applicable box(es) below):

❑ **Physician's office** **OR** ❑ **Specialty Pharmacy – PropriumRx**

Use of samples to initiate therapy does not meet step-edit/preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.